|
Model | Before renal denervation | Renal denervation | After renal denervation | Receptor assay | Reference |
|
Normotensive rats Hydropenic rats (volume deficient state) | — | Unilateral | Increase of density, number, or affinity of glomerular Ang II receptors | Ligand binding assay | [4, 61, 66, 67] |
|
Spontaneously hypertensive rats | — | Acute in left kidney | Increase of AT1R functionality in the renal vasculature | — | [65] |
|
Spontaneously hypertensive rats | Decrease of vasoconstrictor response to vasoactive agents by carvedilol | Acute in left kidney | Increase the sensitivity of renal AT1R to the vasoactive agents | — | [7] |
|
Spontaneously hypertensive rats | — | Bilateral (chemically) | Downregulate AT1R in plasma and PVN | Western blotting (antibodies against AT1R: No. ab124505, Abcam) | [107] |
|
2K1C rats | Upregulate the expression of AT1R and AT2R mRNAs in ischemic kidney | Unilateral | Normalize the expression of AT1R and AT2R mRNAs in ischemic kidney | Quantitative real-time PCR | [76] |
|
2K1C rats | Upregulate Ang II receptor expression in RVLM and PVN | Unilateral | Decrease of Ang II receptor expression in RVLM and PVN | Quantitative real-time PCR | [76] |
|
Chronic foot shock-induced hypertension in rats | Increase of AT1aR mRNA and protein expression in cerebral cortex and hypothalamus | Bilateral | Decrease of AT1aR mRNA and protein expression in cerebral cortex and hypothalamus | AT1a mRNAs: real-time PCR Expressions of AT1a: western blotting (primary antibody: Santa Cruz Biotech, Inc.) | [108] |
|
Chronic HF rabbit model | Increase of the proportion of AT1R to AT2R expression in renal cortex | Unilateral | Decrease of the AT1R expression and increase of the AT2R expression in the renal cortex | Antibody-based method (primary antibodies: AT1R and AT2R rabbit polyclonal antibody, 1:500, Santa Cruz) | [75, 83] |
|
HF canine model | Upregulate mRNA expression and protein levels of AT1R hypothalamus | Catheter-based renal denervation | Decrease of mRNA expression and protein levels of AT1R in the hypothalamus | AT1 mRNAs: real-time PCR Protein expressions of AT1R: western blot | [81] |
|
HF rats model | Upregulating mRNA expressions of AT1R in lamina terminalis and hypothalamic PVN | Bilateral | Reduced mRNA expressions of AT1R in lamina terminalis and hypothalamic PVN | Real-time PCR. | [112] |
|
Ren-2 transgenic hypertensive rats with HF | No changes in renal Ang II receptor binding characteristics | Bilateral | Unchanged | Radioligand binding assay | [69] |
|
Cardiomyopathy rats model | — | Bilateral | Downregulation of cardiac AT1R | Western blot (Abcam Inc, UK) | [74] |
|
Cardiorenal syndrome rats model | Upregulation of AT1aR mRNA in the left ventricle and downregulation in the renal cortex | Bilateral | Ameliorate AT1aR mRNA in the left ventricle and downregulation in the renal cortex | Real-time PCR | [88] |
|
MI rats model | — | Bilateral | Decrease of AT1R in heart | Western blot (primary antibody: AT1R, 1:1000; Abcam, UK) | [113] |
|
Aortic regurgitation rats model | Increase of AT1aR mRNA in renal cortical tissue | Chronic unilateral | Suppressing the increased level of AT1aR mRNA | Real-time PCR | [90] |
|
PKD rats model | Decrease of the mRNA expression level of AT1aR in kidney | Bilateral | No change | Real-time quantitative PCR | [95] |
|
Diabetic rats model | Decrease in number of Ang II glomerular sites | Unilateral | Increase in the number of Ang II glomerular sites | Receptor-binding assay | [67] |
|
Diabetic rats model | Increases in AT1R expression in the cortical and outer medullary collecting duct | Chronic bilateral | Decrease of the expression of AT1R in the cortical and outer medullary collecting duct | Immunohistochemistry assay (monoclonal AT1R: ab9391; 1:20, Abcam) | [96] |
|
Sheep thyroidectomy fetuses model | Change AT1R and AT2R mRNA and protein levels in kidney | Bilateral | Regulate AT1R and AT2R receptor expression in kidney | AT1 and AT2 mRNA: RNase protection assay (RPA kit III; Ambion) AT1 and AT2 proteins: western blot | [103] |
|